Eli Lilly’s weight-loss drug reduces risk of developing diabetes in long-term trial
Related media - Latest news In a recent long-term research study published Tuesday, Eli Lilly reported that its popular weight-management drug significantly reduced the incidence of type 2 diabetes by 94 percent among overweight or obese adults who had prediabetic symptoms, compared to a control group that received a placebo. The late-stage study explored the effects of tirzepatide, the active compound in both Eli Lilly’s Zepbound weight-loss shot and the diabetes treatment Mounjaro. Over about three years, participants who received the highest weekly dose of tirzepatide experienced an average reduction in body weight of 22.9 percent, while those who took…